

DACC NEWS

Volume 28, Number 1, March 2012

ANIMAL CLINICAL CHEMISTRY

A DIVISION OF AACC

2012 Spring Meeting Edition

Message from the Chair

As I walked into work this morning, I had to remind myself that it is March. The daffodils and crocuses were in full bloom. And, as I look out the window, I note a group of people jogging in shorts and t-shirts. This speaks to the unusually warm



winter we've experienced in the East. I must admit that I erased the next two paragraphs that I had originally written at this point. They were a fairly negative commentary regarding the economy and its impact on the recent DACC decision to discontinue the Fall Meeting didn't leave me with such a warm feeling as the

weather. But now I will redirect. There are many things in life we can't control, including the economy, but as my father used to remind me, you can always choose your attitude.

I choose to be optimistic, even in the face of current challenges. I still feel privileged to work in a medical field where my work positively impacts the lives of others. I also feel privileged to be a part of the DACC and to have an op-

In This Issue:

[Pg.3 Update from the Executive Committee](#)

[Pg.5 Spring Symposium Program Schedule](#)

[Pg.7 Spring Meeting Presentation Abstracts](#)

[Pg.11 Hematology Article](#)

[Pg.13 Inductee to the ESVCP Hall of Fame](#)

[Pg.13 Travel Award Winner 2011](#)

[Pg.14 Images from the 2011 Fall Symposium](#)

portunity to lead and participate in the programs we offer to members. My first association with the DACC was as an invited speaker (approximately 1996). Little did I know that I'd be asked to be secretary of this organization very shortly thereafter. I made the choice to say yes, and was pleasantly surprised by what I found. Certainly there was an element of work involved, but it also gave me an opportunity to meet people with a broad range of skill sets and an incredible passion for what they were doing. It became an important connection for me, and I looked forward to seeing people at the Spring, Annual, and Fall meetings. I still feel that connection, and that it was so difficult to make a decision to discontinue the Fall Meeting.

I continue to look at this challenge as our next opportunity. Over the past few years, we



(Message from the Chair continued...) have found it difficult to recruit for our Chair-Elect position. This is not an uncommon problem for many organizations, particularly those staffed by volunteers. By decreasing our meeting commitment to a Spring Scientific Session and events at the Annual meeting, we create an environment where we may potentially attract more leaders. Under this new remit, the Chair and Chair-Elect will work together to plan the Spring Meeting. This provides a natural mentoring relationship for the Chair-Elect and reduces the burden on any single individual. We will be soliciting for a Chair-Elect candidate for 2012 beginning this summer. I encourage you to consider this role. If you ask anyone who has served in the role, I believe you'll find that it was a positive experience. And now you have someone to help you learn the ropes, and guide you through the first year. What more could you ask for?

I hope many of you will be joining us for the Spring Meeting. Siemens will host a Multispecies User's meeting on Thursday, April 26. On Friday March 27, Boehringer-Ingelheim Pharmaceuticals in Ridgefield CT will host the Spring Meeting, which is titled: "Biomarkers: Past, Present, and Future". I want to thank Barbara Litzenberger for bringing together another stellar agenda of speakers. Please look further in this Newsletter for the full meeting agenda and speaker abstracts. The one topic most requested by DACC members has been biomarkers. This is your opportunity to hear how we've progressed with biomarker development and network with DACC colleagues.

So what will we do with our Fall without a DACC meeting? We continue to examine that question. One answer may be to submit a program for the ASVCP annual meeting. I received comments from a few ASVCP members when the notice of discontinuation of the Fall Meeting was sent on the ListServ. They were quite positive and encouraged us to keep in touch and actively submit a program for consideration. The outreach was quite genuine and I believe there is a great opportunity for partnership. Although we can't control the economy, we can think differently about how we can respond to the pressure. And on that, I'll end with a quote from Jimmy Dean, "I can't change the direction of the wind, but I can adjust my sails to always reach my destination". The destination for the DACC is still an enviable one. I encourage you to participate more fully and reap the benefits of involvement and choice. ❖ Kay



Pre-Meeting Activities

Thursday – April 26th, 2012

Siemens Multispecies User's Group Meeting

Ethan Allen Hotel

8:30am – 3:00pm

Scientific Presentations and Lunch

Hosted by

Siemens Healthcare Diagnostics

Volunteer to Make a Presentation Contact:

Dave Zelmanovic, zelmanov@aol.com, 845-425-9711

Registration or Other Info Contact:

Christopher.Halpin@siemens.com, 908-358-4230

DACC Executive Committee Meeting

Ethan Allen Hotel

Room: Arlington

5:00pm – 6:00pm

Open to All Members!

Join in the Planning of DACC Activities!

DACC Mixer/ Buffet Dinner and Meet the Speakers Reception

Ethan Allen Hotel

Room: Essex/Conservancy

6:00pm – 8:00pm

Free Drinks and Food!

Hosted by

IDEXX Laboratories

Please RSVP Planned Attendance

by April 13th to

Barbara Litzenberger

Litzenbb@Princeton.Huntingdon.com

RSVP is Not Necessary if You Can't Make It

An Important Update from a Recent DACC Executive Committee Meeting

Fall DACC Meetings to be Discontinued

At the DACC Executive Committee meeting in January, we made the difficult decision to discontinue the practice of offering two scientific symposiums each year independent of the Annual Meeting. Since the Spring Meeting is linked to the Siemens User Group Meeting making it an attractive 2-day event, we opted to discontinue the Fall Meeting.

Through feedback we know that our scientific sessions are valuable to our membership and that the content of our meetings has continued to be excellent. However, several factors weighed strongly in the decision to discontinue the Fall symposium. First and foremost was the current economic impact. Many companies are either not supporting or minimizing the amount of travel available for scientific meetings. As such, paid attendance has continued to shrink. Concurrently, costs associated with hosting these sessions have increased. More speakers require paid expenses as more of their companies have ceased to cover ever increasing travel expenses. Consequently, over the past few years, the DACC budget has run in the red because our meeting costs have exceeded revenues.

Another reason for the decision was the difficulty in recruiting new leaders for the Chair-Elect/Chair position. We recognize that planning scientific symposiums is a time-consuming activity and that many otherwise willing potential candidates feel they do not have the time to devote to planning 2 sessions coupled with the requirements of their day job. By allowing both the Chair-Elect and Chair to share the job of organizing one really great meeting each year, we minimize the burden on any single individual. Hopefully, this will encourage others to step up to the Chair-Elect position as the benefits far out-weigh the burdens.

The last reason for this decision was a potential conflict with the ASVCP meeting that is also held in the Fall. We discussed the possibility of submitting presentation topic proposals to the ASVCP meeting in lieu of the DACC Fall Meeting. That discussion is still very active, as it offers the potential of continuing to provide scientific sessions that are relevant to our membership, does not compete with ASVCP attendance, and it minimizing meeting costs and session planning activities.

What can you expect for 2012? A great **Spring Meeting** titled ***Biomarkers: Past, Present and Future*** hosted by Boehringer-Ingelheim Pharmaceuticals in Ridgefield CT on Friday, April 27, as well as an excellent scientific symposium and a Lunch and Learn session at this year's AACC Annual Meeting in July. We hope to see you at one or both of these events.

Kay Criswell, Chair
DACC Executive Committee



A
BIG
DACC
THANKS!

To:
**Boehringer-Ingelheim
Pharmaceuticals**

For Hosting the 2012 DACC Spring Meeting at their Ridgefield CT Facility and for Providing Printed Handouts, Breakfast, and Lunch to the Attendees

To:
IDEXX Laboratories

For Their Contributions to the DACC Mixer/Bufferet Dinner and Meet the Speakers Reception the Night Prior to the 2012 Spring Meeting



DACC Supporters

SUSTAINING SPONSORS
Siemens Healthcare Diagnostics

Benefactors
Hoffmann-La Roche, Inc.
Huntingdon Life Sciences, Inc.
Johnson & Johnson Pharm Res and Dev
Merck & Co., Inc.
Novartis Pharmaceuticals Corporation
Pfizer Global Research & Development

Patrons
GlaxoSmithKline
IDEXX Laboratories
Merck Research Laboratories
Sysmex America, Inc.

Contributors
Kay Criswell –Pfizer Global Res & Dev

Friends
Michael Aleo –Pfizer, Inc.
Gregory Bannish –Huntingdon Life Sciences
Eric Blomme –Abbot Laboratories
Mark Collinge –Pfizer, Inc.
Alison Harrill –Hamner Institutes for Health Sciences
Jon Kimball –The Potter-Hawkins Group
Thomas Li –Hoffmann-La Roche, Inc.
Michael Linn –Hoffmann-La Roche, Inc.
Calvert Loudon –J&J PRD
Carmen Raventos-Suarez –Pfizer, Inc.
Shelli Schomaker –Pfizer, Inc.
Eric Schultze –Lilly Research Labs
Chris Stevenson –Pfizer, Inc.
Sharon Sokolowski –Pfizer, Inc.
Jessica Whritenour –Pfizer, Inc.



2012 DACC Spring Meeting

Biomarkers: Past, Present & Future

Thursday – April 26

DACC Executive Committee Meeting

5:00pm – 6:00pm

Ethan Allen Hotel, Danbury CT, Arlington Room

Open to All Members! Come Join in the Planning of DACC Activities!

DACC Meet the Speakers and Poster Travel Award Reception/Mixer

Ethan Allen Hotel, Danbury CT, Essex/Conservancy/Gazebo Courtyard 6:00pm – 8:00pm

Supported by **IDEXX Laboratories**

Free!

RSVP, Yeses Only, to Barb at litzenbb@princeton.huntingdon.com by April 13

Friday – April 27

Registration and Continental Breakfast

8:00am – 8:30am

Boehringer-Ingelheim Pharmaceuticals

GPS Address: 39 Briar Ridge Rd, Danbury, CT

Check in at North Security Gate, Host Site Contact: Amy Hudak

Welcome & Introductions

8:30am – 8:45am

Kay Criswell, Welcoming Address, DACC Chair, Pfizer Global Research & Development

Barbara Litzenberger, Symposium Moderator, DACC Past-Chair, Huntingdon Life Sciences

Translational Biomarkers in the Development of New Medicines

8:45am – 9:30am

Mark Fidock, PhD, Group Director and Global Head Biomarker and Translational Sciences
Huntingdon Life Sciences, Huntingdon, UK

Measurement of Protein Biomarkers in Small Samples by High-Throughput Mass Spectrometry: Expanding the Diagnostic and Toxicologic Proteomes

N. Leigh Anderson, PhD, Chief Executive Officer

9:30am – 10:15am

Plasma Proteome Institute, Washington DC

<Break>

10:15am – 10:45am

miRs and mRNAs as Biomarkers

10:45am – 11:30am

Igor Mikaelian, DVM, MSC, DACVP, Principal Scientist

Hoffmann-La Roche, Inc., Nutley NJ

New Technologies for Biomarker Validation

11:30am – 12:15pm

Steven R Binder, PhD, Director, Technology Development, Clinical Diagnostics Group

Bio-Rad Laboratories, Hercules CA

2012 DACC Spring Meeting Biomarkers: Past, Present & Future

Friday – April 27

<Lunch>

12:15pm – 1:30pm

Building a Biomonitoring Program for Drug Development

1:30pm – 2:15pm

Jonathan Phillips, PhD, Principal Scientist, Nonclinical Drug Safety
Boehringer-Ingelheim Pharmaceuticals, Ridgefield CT

Identifying Biomarkers of Drug Induced Vascular Injury

2:15pm – 3:00pm

Sharon Sokolowski, BS, Principal Scientist, Drug Safety R&D
Pfizer Inc., Groton CT

Questions and Closing Remarks

3:00pm – 3:15pm

Barbara Litzenberger, DACC Past-Chair, Huntingdon Life Sciences
Kay Criswell, DACC Chair, Pfizer Global Research & Development

D
A
C
C

F
A
L
L

M
E
E
T
I
N
G

2
0
1
1



Johnson & Johnson
PHARMACEUTICAL RESEARCH
& DEVELOPMENT, L.L.C.



Meeting Abstracts

DACC Spring Meeting Friday, April 27, 2012

Translational Biomarkers in the Development of New Medicines

Mark Fidock, PhD

Group Director and Global Head Biomarker and Translational Sciences
Huntingdon Life Sciences, Huntingdon, UK

This presentation will describe the current challenges facing the Pharmaceutical Industry including a potential solution. Through the strategic development and use of Biomarkers that describe the pharmacology of the therapeutic mechanism; therefore ensuring the project hypothesis is tested in the clinic,

with confidence. To exemplify these principles, a case study from the area of inflammation will describe how Biomarker data was employed for key decision making during the TLR7 drug development program. ❖

Measurement of Protein Biomarkers in Small Samples by High-Throughput Mass Spectrometry: Expanding the Diagnostic and Toxicologic Proteomes

N. Leigh Anderson, PhD

Chief Executive Officer
Plasma Proteome Institute, Washington, DC

The current clinical plasma proteome consists of approximately 200 different proteins or about 1% of the baseline human proteome: 109 proteins measured by FDA-cleared or approved assays and 96 proteins measured using widely-available laboratory developed tests. However the rate at which new protein analytes achieve FDA approval has remained essentially constant over the past 15 years at 1.5 proteins per year, insufficient to meet important diagnostic and prognostic needs and suggesting a failure of the clinical validation process for novel candidate biomarkers. Similar slow progress has characterized the search for better biomarkers of toxicity in animals. Recently, new approaches to protein measurement based on mass spectrometric

(MS) detection have been developed that allow rapid creation of panels of biomarker assays with very high structural specificity and true internal standardization, while consuming very small amounts of sample. Specific enrichment prior to MS (e.g. of tryptic peptides with anti-peptide antibodies in the SIS-CAPA method) can provide sensitivity equivalent to sandwich immunoassays while transcending their major limitations. The generality, strengths and limitations of affinity-MS point to a growing role in validating novel candidate biomarkers, in replacing interference-prone clinical immunoassays, and in implementing assay panels for clinical and pre-clinical applications. ❖

**Register for the Spring Meeting
Via the AACC website:**

<http://aacc.org/events/meetings/Pages/7259.aspx#>

Reserve a Room at Ethan Allen Hotel

21 Lake Avenue Extension (Exit 4 I-84), Danbury, CT, 203-744-1776

www.EthanAllenHotel.com

Discount Group Code: "**BIBiomarkers**"



Meeting Abstracts

DACC Spring Meeting Friday, April 27, 2012

miRs and mRNAs as Biomarkers

Igor Mikaelian, DVM, MSC, DACVP

Principal Scientist

Hoffmann-La Roche, Inc., Nutley, NJ

Quantification of miRNA and mRNAs in body fluids is the latest biomarker frontier in drug safety assessment. The presentation will review microRNA biogenesis, the challenges associated with sample collection and microRNA measurement, and review the microRNAs that have been proposed as biomarkers of organ toxicity and cancer. The reliability and quality of the collection, extraction and measurement methods are the most critical points when trying to accurately determine the level of expression of microRNAs in body fluids. This activity, although a pre-

requisite toward the establishment of microRNA biomarker signatures, is still in flux. Therefore, the many candidate biomarkers published recently are of questionable value. I will summarize the current literature on the collection and extraction methods for microRNAs and present the results of our laboratory. These issues are tackled collectively through the scientific community, for example in the C-Path/PSTC forum which serves the biomarker efforts of the pharmaceutical industry. ❖

New Technologies for Biomarker Validation

Steven R Binder, PhD

Director, Technology Development, Clinical Diagnostics Group

Bio-Rad Laboratories, Hercules CA

Today we face challenges converting the knowledge gained from genomics and proteomics into useful laboratory tests, for both clinical trials and clinical diagnostics. The challenges include:

- 1) Obtaining very high sensitivity for many newly discovered proteins.
- 2) Obtaining precise measurements of DNA and RNA to quantitate small differences that may have significant pathological consequences.
- 3) Developing methods capable of making multiple

simultaneous measurements, in order to conserve samples and increase throughput.

- 4) Reducing the time required to develop antibody pairs for use in highly specific immunoassays of new biomarkers for diagnostic applications.

In my presentation I will discuss recent developments in single molecule detection, label-free immunoassays, and protein arrays, and how these new technologies will help us address these challenges. ❖

Election Results from Last Fall, Meet 2012's Newest Officers:

Chair-Elect

Richard Giovanelli, Pfizer

Secretary

David Adams, GlaxoSmithKline

Nominating Committee

Rosemary Nicklaus, Roche
Joseph Sansone¹

The DACC Membership Offers a Big *THANK YOU* to its Outgoing Officers:

2011 Past-Chair

Mike Bieraugel, Allergan

2011 Secretary:

Renée Pearson, Pearson Consulting

2011 Chair of Nominating Committee:

Roseanne Riley, Bristol-Myers Squibb

¹: Appointed to replace Kay Criswell while she serves on the Executive Committee



Meeting Abstracts

DACC Spring Meeting Friday, April 27, 2012

Building a Biomonitoring Program for Drug Development

Jonathan Phillips, PhD

Principal Scientist, Nonclinical Drug Safety
Boehringer-Ingelheim Pharmaceuticals, Ridgefield CT

Monitoring biological pathways and processes in the body has become increasingly accessible. New technologies allow us to obtain more sensitive measures, consistent results and access to diverse biomolecular classes. I will discuss technical platforms and approaches used to identify biomarker

candidates. I will also discuss what criteria are considered when designing and vetting biomarker programs for drug development. These include potential for clinical translation and ongoing efforts to accelerate regulatory acceptance. ❖

Identifying Biomarkers of Drug Induced Vascular Injury

Sharon Sokolowski, BS

Principal Scientist, Drug Safety R&D
Pfizer Inc., Groton, CT

Today we face challenges converting the knowledge gained from genomics and proteomics into useful laboratory tests, for both clinical trials and clinical diagnostics. The challenges include:

- 1) Obtaining very high sensitivity for many newly discovered proteins.
- 2) Obtaining precise measurements of DNA and RNA to quantitate small differences that may have significant pathological consequences.
- 3) Developing methods capable of making multiple

simultaneous measurements, in order to conserve samples and increase throughput.

4) Reducing the time required to develop antibody pairs for use in highly specific immunoassays of new biomarkers for diagnostic applications.

In my presentation I will discuss recent developments in single molecule detection, label-free immunoassays, and protein arrays, and how these new technologies will help us address these challenges. ❖

Maria Helfrich Retires from BMS

After 28 years in the Mount Vernon, IN Clin Path Lab of Bristol-Myers Squibb, our friend and distinguished colleague Maria D. Helfrich retired in November, 2011.

Maria graduated from the University of Evansville with a BS in Medical Technology in 1976. After working 7 years at Welborn Baptist Hospital in Evansville, Maria was hired to work in the Clin Path Lab at BMS (it was Mead Johnson Pharmaceuticals at the time, then Bristol-Myers, then Bristol-Myers Squibb Co.). When she retired, she was a Senior Research Scientist, supervising the medical technology staff in the Mount Vernon lab.

A regular attendee at DACC meetings, Maria also held elective office in several capacities in service to the DACC and AACC. Her plans for retirement include catching up on "projects" at the family homestead/farm, working out at the gym and visiting her three grown daughters in Scottsdale, St. Louis and Baltimore.

Wish her the best at maria.helfrich@yahoo.com
~Chris Perigard



Michael Bieraugel Receives the 2011 Royden N. Rand Past-Chair Award

This named award honors the service of the Past-Chair and pays tribute to the memory of Dr. Royden N. Rand, the President of the AACC who initially sanctioned the formation of the original ad hoc Laboratory Animal Clinical Analysis Group in 1976. This award is presented to the DACC's immediate Past-Chair to honor his or her contributions to the field of animal clinical laboratory science throughout their career and to acknowledge the recipient's contributions to the Division of Animal Clinical Chemistry. Each division Chair sacrifices time to promote and provide education in the area of Animal Clinical Chemistry, and foster communication and networking among division members as per the Division mission. Mike's contributions to supporting the DACC's educational mission began when he joined the *DACC News* Editorial Committee in 2008.



During his tenure as Chair-Elect (2009), Chair (2010), and Past-Chair (2011) he has demonstrated that he is very timeline and goals driven. Mike coordinated three scientific symposiums for the DACC. In 2009, as Chair-Elect, he was the principal planner and moderator for the Spring symposium titled *The Expanding Role of Clinical Pathology: Adding Value to the Drug Discovery and Development Process*, as well as the Fall symposium titled *Biological Marker Assay Development and Validation: Systems Biology, Proof of Concept, Method Optimization and Regulatory Qualification Considerations*. In 2011, as Past-Chair he successfully developed the program for the Spring meeting entitled *Oncology Drug Development: Animals Models, Carcinogenicity, Cardiotoxicity and More*. Finally he organized the Annual Meeting Lunch & Learn Sessions in 2010 and 2011, the latter dubbed *DACC Listserv LIVE*. Mike has also been a key contributor to numerous DACC operating committees. In the last three years he has been involved in the Executive, the Scientific and Long Range Planning, Nominating, and Editorial Committees.

Mike manages the Clinical Pathology laboratory for Allergan's Drug Safety Evaluation department. He is responsible for writing and editing textual data interpretations from analyses of hematology, clinical chemistry, coagulation, urinalysis, and immunoassays in support of drug discovery and nonclinical safety studies. He consults internally on issues related to study design, specimen integrity, laboratory analysis, and regulatory compliance. In addition, he is responsible for his lab's budgeting, equipment purchasing, hiring, metrics tracking, QA/QC, analytical method development and software validation.

So you see, Mike is clearly a leader in every sense of the word and we, as members of the DACC, are all lucky to have experienced his leadership and smooth manner. On behalf of the DACC, I was honored to present this award to Mike during the 2011 Fall Symposium. I know those of you who were able to attend extended a personal congratulations to Mike. If you were not able to attend the fall meeting, please extend your words of congratulation and appreciation when you see him which I am sure will be soon and often. Mike will undoubtedly continue to contribute to the DACC by attending Executive Committee and General Business meetings whenever the opportunity presents itself to him. Thank you Mike!

**Respectfully submitted,
Barbara Litzenberger
DACC's 2011 Chair**



Contemporary Challenges in Animal Hematology

A Position Piece by Ian Giles, MD and Elizabeth Wiet MLS(ASCP), DACC Member

Numerous challenges and opportunities exist to contribute additional information from animal hematology testing that exposes pathophysiological mechanisms. The pressures of drug discovery require the best assessment of a compound's physiological effects informed by the best available *in vitro* diagnostic technology. There are obvious constraints of working with small sample volumes and multiple species with different cellular characteristics.


Advancements in hematology cell counters provide the opportunity to allow early insights into underlying pathological mechanisms on first pass analysis using small sample volumes. By quantifying and assessing immature blood cell precursors, as well as counting mature cells, the potential exists to gather clues related to the mechanisms responsible for abnormal results.

There exists a great need for hematology analyzers that require smaller sample volumes and yet provide more parameters from a single analysis. Dilution of

samples from small animals presents the risk of error. Additionally, diagnostic sensitivity and specificity may be compromised if the analyzer cannot test pre-diluted samples. Analyzer efficiency should be understood in terms of expanding the number of reported parameters and clinical insights available from each sample analysis.

The specific requirement for veterinary hematology is to expand the number of relevant parameters using classification algorithms specific to the test animals. Antibody-based flow cytometry provides the ability to classify specific immature blood cells, but can be subjective and costly to perform. The emergence of flexible gating in automated hematology platforms may provide additional opportunities for a laboratory to optimize results for multiple species or strains.

Flow technology coupled with flexible gating may provide better delineation of differential results for those conditions where cellular populations are not distinct.



(continued on page 12). . .

The DACC Needs YOU!

Members Are Needed to Serve the DACC in the Following Capacities:

Elected Office

Candidate for Chair-Elect

Candidate for Treasurer

Candidate for Nominating Committee Member

Volunteer Position Available

Membership Committee Member

Your Participation in OUR Division is Important to Ensure Continued Quality of the DACC's Business and Educational Activities

Contemporary Challenges in Animal Hematology

(continued from page 11)

Hematology studies may often include both bone marrow examination and whole blood analysis to give a complete picture of disease pathogenesis, drug responses and risk assessment. The bone marrow is a highly proliferative tissue; therefore, monitoring changes in hematopoiesis can be an indicator of potential side effects of compounds. Parameters are becoming available on fully automated hematology analyzers that demonstrate the presence of immature blood cells in peripheral blood, allowing insights into the effect of a compound on blood cell production in the marrow.

Bone marrow production not only depends on healthy hematopoietic progenitor cells, but also reflects the status of other physiological mechanisms. For example, normal red cell production also requires production of erythropoietin and available iron. Reticulocyte counts combined with the more recently available reticulocyte hemoglobin can reflect the status of erythropoietic function, and iron availability for incorporation into red cell hemoglobin. Tracking this expanded information during drug discovery may provide important information about risk and tolerability of the final product.

Monitoring immature blood cells in peripheral blood

allows us to gain insights into pathophysiological mechanisms underlying disease processes in a minimally invasive way. Information about immature cell lines can therefore be used to guide the development of drugs using comprehensive diagnostic information from a small sample. Interpretation of immature cell count data can likely provide early insights into pathophysiological mechanisms, and may ultimately enable therapy decisions to be made with a firm understanding of underlying pathophysiological mechanisms.

Immature cell response is rapidly becoming a mainstay in both preclinical and clinical drug assessments. Validation of the existing functionality which is being applied in the clinical realm can be applied in the pre-clinical environment. It is hoped that this will equate drug-induced responses seen early in the drug development cycles in animal models to the clinical responses monitored post-launch. The future is open for discovery and leaves the question; how can routine IVD testing help us to develop effective and safe therapies and optimize treatment and monitoring of rapidly progressing diseases? ❖

DACC Events at the 2012 Annual Meeting in Los Angeles

Monday, July 16, 2012, 8:30–10:30am

DACC Executive Committee Meeting, JW Marriott Hotel Los Angeles

Monday, July 16, 2012, 12:30–3:30pm

DACC General Business Meeting / Lunch & Learn, JW Marriott Los Hotel Los Angeles

Monday or Tuesday Evening, TBD

DACC Awards Presentation Reception and Mixer Recognizing an Outstanding Contributor to Animal Clinical Chemistry, hosted by Siemens Healthcare Diagnostics

Wednesday, July 18, 2012, 10:30am–12:00pm

DACC Morning Symposium "Benefits of Biorepository Utilization and Genetically Diverse Models as Predictors of Drug Safety and Efficacy", The session will highlight the utilization of genomic approaches to improve efficacy and safety prediction in drug development. Targeted sequencing, gene expression as biomarkers, and preclinical models that mimic human genetic diversity offer great promise in targeting the right patient population with the right medication.

- 1) **"Novel Genetic and Proteomic Biomarker Approaches and Biorepository Utilization to Predict Treatment Efficacy in Clinical Trials"**, Joseph D. Paulauskis, PhD, Vice President, Research & Biobanking, The International Genomics Consortium, Phoenix, AZ
- 2) **"Using the Mouse Model of the Human Population to Predict Drug-Induced Liver Injury"**, Karissa Adkins, PhD, Associate Research Fellow, Pfizer, Inc., Groton, CT

Jerry Kaneko Inducted into the ESVCP Hall of Fame

Jiro J. Kaneko, DVM, PhD, DVSc (h.c.) was selected to be one of the first inductees into the recently established European Society of Veterinary Clinical Pathology (ESVCP), Hall of Fame. Four awards were presented to two Europeans and two Americans during the 2011 European Society Meeting in Dublin. In addition to Dr. Kaneko, the other award recipients were Mary Christopher, Jean-Pierre Braun, and Harold Tvedten.

Dr. Jiro “Jerry” Kaneko is respected world-wide for his contributions to the practice and teaching of students in Clinical Pathology. He received his AB (Chemistry) from the University of California, Davis in 1952 and went on to receive his DVM (1956) and PhD (Comparative Biochemistry) (1959) from the same university. Jerry has spent his career at the University of California, Davis and had many leadership roles. His book “Clinical Biochemistry of Domestic Animals”, now in its 6th edition, is essential reading for veterinary clinical pathologists. He has authored or coauthored over 175 other publications. He has influenced an entire generation of scientific leaders and veterinary medicine professionals.



Jerry has received many honors in his career including the DACC “Award for Outstanding Contributions to Animal Clinical Chemistry”. He was the first honoree to receive the DACC’s highest award.

Although Dr. Kaneko has been Professor Emeritus, School of Veterinary Medicine, University of California, Davis since 1994, he is still active and is a long time DACC member. He presently serves the division as a member of the awards committee. Jerry has served the field of veterinary clinical pathology for over half a century. His legacy of excellence in research, training, and education is incalculable. Join us in congratulating Jerry in this recognition by the ESVCP. ❖



Jeffrey Bock Receives the DACC 2011 Travel Award at the Fall Meeting

For the Best Poster Presented at the Annual Meeting
***“Comparison of Sysmex Flow Cytometric and Microscopic
Bone Marrow Differentials in Wistar Rats”***

Authors: J.H Bock, K.A. Criswell, R.P Giovanelli, Pfizer Inc., Groton, CT

Images from the 2011 Fall Symposium “Hepatotoxicity: Mechanisms, Predictivity, and Biomarkers”



Presenter:
Hartmut Jaeschke



Moderator:
Kay Criswell




Presenter:
Robert Roth




Presenter:
Shelli Schomaker




L-R: A. Harrill, K. Criswell, S. Schomaker, E. Blomme,
H. Jaeschke, R. Roth, M. Aleo, J. Whritenour



Presenter:
Jessica Whritenour




Presenter:
Alison Harrill



Presenter:
Eric Blomme



Presenter:
Michael Aleo



Short Scripts



**SOCIETY of TOXICOLOGIC
PATHOLOGISTS
ANNUAL MEETING**
Boston, MA
June 24-28, 2012



**Volunteers are needed for
DACC committees. Join your
colleagues in determining
the future direction of
YOUR division.**



**AMERICAN ASSOCIATION
for CLINICAL CHEMISTRY
ANNUAL MEETING**
Los Angeles, CA
July 15-19, 2012



**AMERICAN COLLEGE of
TOXICOLOGY
ANNUAL MEETING**
Orlando, FL
November 4-7, 2012



**ACVP / ASVCP
ANNUAL MEETING**
Seattle, WA
December 1-5, 2012



DACC Mixer/Bufferet Dinner and Meet the Speakers Reception

**Thursday 4/26/2012 6:00pm
Ethan Allen Hotel**

21 Lake Avenue Extension (Exit 4 I-84), Danbury, CT

Free !! Send RSVP for the Reception to Barb at
litzenbb@princeton.huntingdon.com

Hosted by

IDEXX Laboratories



2012 DACC Fall Elections
This is the Year YOU Should Run for Office
The Division Depends on YOUR Volunteerism!
See Which Positions Are Open On Page 11



DACC NEWS

AACC's Division of Animal Clinical Chemistry



DACC NEWS Editor Emeritus

Robert E. Emmons
585-924-5019
reemmons@frontiernet.net



DACC NEWS Editor

Mike Bieraugel
714-246-6051
bieraugel_michael@allergan.com



DACC NEWS Associate Editor

Jon P. Kimball
919-967-4016
jonkimball@msn.com

DACC 2012 Executive Committee

Chair

Kay Criswell
Pfizer Global Res. & Dev.
860-686-9430
kay.criswell@pfizer.com



Chair-Elect

Richard P. Giovanelli
Pfizer Global Res. & Dev.
860-686-2176
richard.p.giovanelli@pfizer.com



Past-Chair

Barbara Litzenberger
Huntingdon Life Sciences
732-371-0852
litzenbb@princeton.huntingdon.com




Treasurer

Lila Ramaiah
732-371-2550
ext 2683
lramaiah@mac.com



Secretary

David F. Adams
GlaxoSmithKline R&D
610-270-7228
david.f.adams@gsk.com



DACC 2012 Committees

Nominating (Year as Chair)

Karen Lynch (2012)
Joe Sansone (2013)
Dave Desmond (2014)
Rosemary Nicklaus (2015)
Barbara Litzenberger (Exec Rep)

Membership

Joe Sansone (Chair)
Rosemary Nicklaus

Fund Raising

Jon Kimball
Doug Neptun
Chris Perigard
Lila Ramaiah (Exec Rep)

Awards

Jon Kimball (Chair)
Jiro Kaneko
Bob Emmons
Doug Neptun

Scientific Program & Long Range Planning

Barbara Litzenberger^{1,2}
Kay Criswell³
Richard Giovanelli⁴
Rosemary Nicklaus
Doug Thudium
Jon Kimball

Principal Organizer: 1: 2012 Spring Symposium, 2: 2012 Annual Meeting Symposium,
3: 2013 Annual Meeting Symposium, 4: 2012 Annual Meeting Lunch & Learn